Safwan Shabab was appointed as Director at LifeStance Health Group, Inc..
“on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.”
LifeStance Health Group, Inc. — fact timeline
Source-grounded facts extracted from LifeStance Health Group, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lori Goltermann was appointed as Director at LifeStance Health Group, Inc..
“on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.”
Thurman Justice was appointed as Director at LifeStance Health Group, Inc..
“on July 2, 2026, the Board appointed Thurman Justice, Lori Goltermann and Safwan Shabab as a directors of the Company.”
Jeffrey Rhodes resigned as Director at LifeStance Health Group, Inc..
“On July 2, 2026, Jeffrey Rhodes notified the LifeStance Health Group, Inc. (the “Company”) board of directors (the “Board”) of his resignation from the Board and all of its committees, effective immediately.”
LifeStance Health Group, Inc. shareholders approved Advisory vote on named executive officer compensation at the 2026-06-02 meeting.
“Proposal 3: Advisory Vote on Named Executive Officer Compensation The stockholders of the Company approved, on a non-binding advisory basis, the Company’s named executive officer compensation. The results of the vote were as follows: For Against Abstain Broker Non-Votes 322,904,359 5,675,861 354,151 29,782,714”
LifeStance Health Group, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.
“Proposal 2: Ratification of the Company’s Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2026. The results of the vote were as follows: For Against Abstain 357,756,707 209,431 750,947”
LifeStance Health Group, Inc. shareholders approved Election of Class II Directors at the 2026-06-02 meeting.
“Proposal 1: Election of Directors The stockholders of the Company elected the director nominees listed below to serve on the Company’s Board of Directors as members of Class II for a term of three years. The results of the vote were as follows: Name of Nominee For Withhold Broker Non-Votes David Bourdon 244,968,319 83,966,052 29,782,714 Robert Bessler 280,015,618 48,918,753 29,782,714”
LifeStance Health Group, Inc. reported the first quarter ended March 31, 2026 results: revenue $403.5 million, net income $14.2 million. Guidance raised.
“for the first quarter ended March 31, 2026. (All results compared to prior-year comparative period, unless otherwise noted) 2026 Highlights and FY 2026 Outlook • Revenue of $403.5 million increased 21% compared to revenue of $333.0 million • Clinician base increased 11% to 8,349 clinicians, a sequential net increase of 309 in the first quarter • First quarter”
Vaughn Paunovich was appointed as Chief Technology Officer at LifeStance Health Group, Inc..
“The Company appointed Vaughn Paunovich to serve as the Company’s new Chief Technology Officer, effective as of June 9, 2025.”
Pablo Pantaleoni departed as Chief Digital Officer at LifeStance Health Group, Inc..
“On May 14, 2025, LifeStance Health Group, Inc. (the “Company”) announced that, effective July 1, 2025 (the “Transition Date”), Pablo Pantaleoni, the Company’s Chief Digital Officer will be leaving the Company.”
Ryan McGroarty was appointed as Chief Financial Officer and Treasurer at LifeStance Health Group, Inc..
“the Board of Directors also appointed Ryan McGroarty as the Company’s Chief Financial Officer and Treasurer, effective as of March 17, 2025”
Kenneth Burdick retired as Executive Chairman at LifeStance Health Group, Inc..
“Mr. Bourdon will succeed Kenneth Burdick, who has served as the Company’s Chief Executive Officer since 2022 and who is retiring from his position, effective as of the CEO Start Date.”
David Bourdon changed role as Chief Executive Officer at LifeStance Health Group, Inc..
“promoted David Bourdon to serve as the Company’s Chief Executive Officer effective as of March 3, 2025”
Danish Qureshi was terminated as President and Chief Operating Officer at LifeStance Health Group, Inc..
“Effective as of June 30, 2024 (the “Separation Date”), Danish Qureshi’s employment as President and Chief Operating Officer of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) terminated.”
LifeStance Health Group, Inc. reported the first quarter ended March 31, 2024 results: revenue $300.4 million, net income ($21.1 million). Guidance raised.
“LifeStance Reports First Quarter 2024 Results SCOTTSDALE, Ariz. – May 9, 2024 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first quarter ended March 31, 2024. (All results compared to prior-year comparative period, unless otherwise noted) Q1 2024 Highlights and FY 2024 Outlook • Revenue of $300.4 million increased 19% compared to revenue of $252.6 million • Clinician base increased 15% to 6,866 clinicians, a sequential net increase of 221 in the first quarter • First quarter visit volumes increased 15% to 1.9 million • Net loss of $21.1 million, primarily driven by stock-based compensation, compared to net loss of $34.2 million”
Danish Qureshi departed as President and Chief Operating Officer at LifeStance Health Group, Inc..
“On May 6, 2024, Danish Qureshi, the President and Chief Operating Officer of LifeStance Health Group, notified the Company of his decision to depart the Company, effective June 30, 2024.”
Teresa DeLuca was appointed as director at LifeStance Health Group, Inc..
“On March 12, 2024, the Company’s Board of Directors (the “Board”) appointed Teresa DeLuca as a director of the Company, effective immediately.”
LifeStance Health Group, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $280.6 million, net income Net loss of $45.0 million. Guidance initiated.
“full year ended December 31, 2023. (All results compared to prior-year comparative period, unless otherwise noted) 2023 Highlights and 2024 Outlook • Fourth quarter revenue of $280.6 million increased 22% and full year revenue of $1,055.7 million increased 23% compared to revenue of $859.5 million • Clinician base increased 18% to 6,645 clinicians, including 227 net”
LifeStance Health Group, Inc. reported the third quarter ended September 30, 2023 results: revenue $262.9 million, net income Net loss of $61.6 million. Guidance raised.
“third quarter ended September 30, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q3 2023 Highlights and FY 2023 Outlook • Total revenue of $262.9 million increased $45.3 million or 21% compared to total revenue of $217.6 million • Total clinicians of 6,418 up 18%, a sequential net increase of 286 in the third quarter • Net loss of”
LifeStance Health Group, Inc. reported second quarter ended June 30, 2023 results: revenue $259.6 million, net income $45.5 million. Guidance raised.
“the second quarter ended June 30, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q2 2023 Highlights and FY 2023 Outlook • Total revenue of $259.6 million increased $50.1 million or 24% compared to total revenue of $209.5 million • Total clinicians of 6,132 up 17%, a sequential net increase of 171 in the second quarter • Net loss”
LifeStance Health Group, Inc. shareholders approved Ratification of the Company’s Independent Registered Public Accounting Firm at the 2023-06-01 meeting.
“Proposal 2: Ratification of the Company’s Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2023. The results of the vote were as follows: For Against Abstain 325,318,177 81,476 285,871”
LifeStance Health Group, Inc. shareholders approved Election of Directors at the 2023-06-01 meeting.
“Proposal 1: Election of Directors The stockholders of the Company elected the director nominees listed below to serve on the Company’s Board of Directors as members of Class II for a term of three years. The results of the vote were as follows: Name of Nominee For Withhold Broker Non-Votes Darren Black 252,313,764 44,403,573 28,968,187 Eric Shuey 270,607,447 26,109,890 28,968,187 Robert Bessler, M.D. 270,587,609 26,129,728 28,968,187”
LifeStance Health Group, Inc. reported the first quarter ended March 31, 2023 results: revenue $252.6 million, net income $34.2 million. Guidance raised.
“the first quarter ended March 31, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q1 2023 Highlights and FY 2023 Outlook • Total revenue of $252.6 million increased $49.5 million or 24% compared to revenue of $203.1 million • Total clinicians of 5,961 up 19%, a sequential net increase of 330 in the first quarter • Net loss of $34.2”
LifeStance Health Group, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $229.4 million, net income $46.7 million. Guidance initiated.
“December 31, 2022. (All results compared to prior-year comparative period, unless otherwise noted) 2022 Highlights and 2023 Outlook • Fourth quarter revenue increased 21% to $229.4 million and full year revenue of $859.5 million increased $192.0 million or 29% compared to revenue of $667.5 million • Clinician base increased 18% to 5,631 clinicians, including 200”
LifeStance Health Group, Inc.: Amended bylaws to update advance notice provisions for universal proxy rules, conform to DGCL, and make administrative changes (effective 2023-03-06).
“On March 6, 2023, the Board of Directors (the “Board”) of the Company approved Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), effective immediately, with such amendments including updates to the advance notice provisions to address the adoption by the Securities and Exchange Commission (the “SEC”) of “universal proxy” rules and other updates to conform with the Delaware General Corporation Law (the “DGCL”) regarding notice of adjourned stockholder meetings and stockholder list requirements.”
LifeStance Health Group, Inc. reported the quarter ended September 30, 2022 results: revenue $217.6 million, net income Net loss of $37.9 million. Guidance reaffirmed.
“for the quarter ended September 30, 2022. (All results compared to prior-year comparative period, unless otherwise noted) Q3 2022 Highlights and FY 2022 Outlook • Revenue of $217.6 million increased $43.8 million or 25% compared to revenue of $173.8 million • Total clinicians of 5,431 up 24%, a net increase of 205 in the third quarter • Net loss of $37.9 million”
J. Michael Bruff changed role as leader of its Business Transformation office at LifeStance Health Group, Inc..
“Mr. Bruff will continue to be employed by the Company as the leader of its Business Transformation office.”
David Bourdon was appointed as Chief Financial Officer and Treasurer at LifeStance Health Group, Inc..
“On November 2, 2022, the Board of Directors of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) appointed David Bourdon as the Company’s new Chief Financial Officer and Treasurer effective as of November 10, 2022 (the “Effective Date”).”
Danish Qureshi was appointed as President at LifeStance Health Group, Inc..
“Danish Qureshi, the Company’s Chief Operating Officer, was appointed as the Company’s President, in addition to his role as Chief Operating Officer.”
Michael Lester departed as President, Chief Executive Officer and Chairman at LifeStance Health Group, Inc..
“Mr. Burdick succeeds Michael Lester, who has served as the Company’s President and Chief Executive Officer and Chairman since 2017 and who is retiring from his officer and director roles effective upon Mr. Burdick’s appointment on the Effective Date.”
Kenneth Burdick was appointed as Chief Executive Officer and Chairman of the Board at LifeStance Health Group, Inc..
“appointed Kenneth Burdick as the Company’s new Chief Executive Officer and Chairman of the Board of Directors.”
Danish Qureshi was appointed as Chief Operating Officer at LifeStance Health Group, Inc..
“On May 20, 2022, the Board of Directors of the Company approved the appointment of Danish Qureshi, the Company’s Chief Growth Officer, as Chief Operating Officer, effective July 1, 2022.”
Gwendolyn Booth retired as Chief Operating Officer at LifeStance Health Group, Inc..
“On May 20, 2021, Gwendolyn Booth, the Chief Operating Officer of LifeStance Health Group, Inc. (the “Company”), notified the Company of her decision to retire from the Company, effective July 1, 2022.”
Seema Verma was appointed as director at LifeStance Health Group, Inc..
“On August 22, 2021, the Company’s Board of Directors (the “Board”) appointed Seema Verma as a director of the Company, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.